Bone Therapeutics’ lead program falls short in knee osteoarthritis
Bone Therapeutics is mulling options for its lead program after the osteoarthritis treatment flopped in a phase 3 study.
Bone Therapeutics is mulling options for its lead program after the osteoarthritis treatment flopped in a phase 3 study.
Total knee replacement surgery just got a bit of an IQ boost.
Solid tumors use several strategies to thrive in harsh conditions. Scientists at the University of British Columbia and BC Cancer Research Institute zeroed in on one of those strategies—the ability of cancer cells to withstand acidic conditions—and found a way to thwart it.
The FDA approved its first nerve stimulation device designed to help people suffering from the lasting effects of stroke to gradually regain control of their arms and hands.
While we may be dreaming of a future where flying drones deliver online purchases and satisfy takeout food cravings within mere minutes, researchers in Sweden are hoping they can be used to outrun ambulances as they respond to heart attacks.
Oncolytic viruses have long held promise for cancer treatment, but their first generation hasn’t quite delivered. Armed with new tools and technology—including 3D printing—Humane Genomics is part of a wave of companies working on oncolytic viruses 2.0.
Virtual reality, meet virtual clinical trials.
DiCE Molecules wants to join the party, albeit not in Las Vegas but on Wall Street, with another preclinical biotech IPO as it goes up against psoriasis giants from Novartis, Eli Lilly and Amgen.
A new group of recalls for a repair piece installed in some of BD’s Alaris infusion pumps joins more than a dozen others on the long list of serious recalls involving the device in the last decade.
Scientists have long been aware that people with Type 2 diabetes are unlikely to develop migraines, and migraine sufferers have a low chance of developing diabetes. But what’s behind the link between those two very different disorders? Scientists at the University of Tennessee believe they’ve found an answer.